Analyst rates Rocket Lab a Strong Buy with a $100 target: backlog rose 52% sequentially to $3.57 billion, while Neutron ...

The following slide deck was published by Altimmune, Inc. in conjunction with this event.

I remain bullish on Enbridge (ENB): at 11.4 times DCF and a 5.68% forward yield, shares could retake the low $50s within 12 ...

The bull case for QQQI: volatility supports monthly income, and its $7.63 trailing distribution implies a 14.96% yield; the ...

Mineral royalty companies offer a capital-light way to capture cash flows tied to energy production and commodity prices.

The bull case for a modified Harry Browne's Permanent Portfolio: real assets, gold and dividend stocks target 7%-8% yields ...

A quick note before we start: on Saturdays, I share what Main Street Alpha members received during the week. And with our ...

Sean Duffy says a L3Harris-managed system upgrade preceded Friday’s ground stop; investigators are checking for installation ...

AVITA Medical is rated Buy with a $20 twelve-month target, driven by a Medicare reimbursement reset effective January 1. RCEL ...

Savara (SVRA) is rated a speculative BUY at $4.72 with a $7 twelve-month price target, anticipating a pivotal FDA decision on ...

Aggressive shelving resets, Direct Store Delivery strategy, and Alani Nu's strong growth have contributed to CELH's ...

Blue Owl Capital Inc. is a "Buy" and now fully covers its $0.23 dividend with distributable earnings, signaling improved ...